Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Sponsor: Sanofi
Summary
Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity
Official title: An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2012-12-14
Completion Date
2033-08-29
Last Updated
2025-06-12
Healthy Volunteers
No
Conditions
Interventions
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Blood draw for the laboratory assessment
Locations (2)
Oregon Health and Science University Site Number : 840001
Portland, Oregon, United States
Investigational Site Number : 250001
Paris, France